Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17430280 | 0.80 | KMT2A (0.39) | PARP10PARP11IDO1ADORA2BNFATC1 | |
| SCHEMBL17430297 | 0.80 | ADORA2B (0.39) | PARP10PARP11IDO1ADORA2BNFATC1 | |
| SCHEMBL17430266 | 0.80 | IDO1 (0.34) | PARP10PARP11IDO1ADORA2BNFATC1 | |
| SCHEMBL17430307 | 0.77 | MAPK14 (0.35) | PARP11 | |
| SCHEMBL17430300 | 0.77 | LMNA (0.43) | NPY5R | |
| SCHEMBL17430278 | 0.77 | PIK3CA (0.42) | — | |
| SCHEMBL17430323 | 0.76 | IDO1 (0.35) | PARP10PARP11IDO1ADORA2BNFATC1 | |
| SCHEMBL17916944 | 0.73 | IDO1 (0.36) | IDO1ADORA2BNFATC1DYRK1A | |
| SCHEMBL17430268 | 0.72 | LPL (0.39) | PARP10PARP11IDO1 | |
| SCHEMBL17430293 | 0.71 | ADORA2B (0.36) | PARP10PARP11IDO1ADORA2BNFATC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | KCNJ1 1472/4885PARP10 1017/4885PARP11 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.